Q1 EPS Estimates for Vor Biopharma Lifted by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – Investment analysts at HC Wainwright increased their Q1 2026 EPS estimates for shares of Vor Biopharma in a research note issued on Tuesday, April 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.88) for the quarter, up from their previous forecast of ($1.65). HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. HC Wainwright also issued estimates for Vor Biopharma’s Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at $4.16 EPS.

Other research analysts have also issued reports about the stock. Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Saturday, April 4th. JPMorgan Chase & Co. cut their target price on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Wells Fargo & Company assumed coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group started coverage on Vor Biopharma in a research note on Monday, March 30th. They set a “buy” rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.56.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $14.97 on Friday. The stock has a market capitalization of $731.25 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The company’s 50-day simple moving average is $14.66 and its 200-day simple moving average is $16.67.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VOR. China Universal Asset Management Co. Ltd. bought a new position in shares of Vor Biopharma in the fourth quarter worth $36,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma in the second quarter worth about $66,000. Chung Wu Investment Group LLC acquired a new stake in Vor Biopharma in the fourth quarter worth about $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in Vor Biopharma in the 4th quarter valued at about $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the sale, the director directly owned 4,555,741 shares in the company, valued at $75,579,743.19. This trade represents a 11.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders sold 2,207,379 shares of company stock valued at $36,632,973. Corporate insiders own 0.45% of the company’s stock.

Key Vor Biopharma News

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: HC Wainwright sharply raised earnings estimates across 2026–2029 (Q1–Q4 2026 EPS forecasts improved to about ($0.88)/($0.94)/($1.02)/($1.10); FY2026 cut loss to ($3.93) from ($7.66); FY2029 now modeled as profitable at $4.16). The firm kept a Buy rating with a $31 target — a material improvement in forward profitability expectations. HC Wainwright raises estimates
• Neutral Sentiment: HC Wainwright trimmed its price target slightly from $32 to $31 while maintaining the Buy — the cut is minor relative to the upside implied by current price levels and appears to be housekeeping rather than a change in conviction. Price target note
• Neutral Sentiment: Market consensus remains mixed but constructive: multiple Buy/Overweight takes exist alongside several Holds, and a consensus price target is materially above current trading — this supports upside if clinical/program milestones or improved guidance follow. Analyst coverage summary
• Negative Sentiment: Significant insider/institutional selling by Ra Capital Management, L.P. has occurred across early–mid April (multiple trades totaling millions of shares sold at ~$15.75–$18.23). These disclosures (Form 4 filings) signal large-holder trimming and increase free float — a clear near-term headwind for sentiment. SEC Form 4 – Ra Capital sales
• Negative Sentiment: Follow-up coverage flagged separate reports of Ra Capital sales (public reporting). Continued selling pressure from a top holder can amplify downside unless accompanied by clear rationale (rebalancing vs. loss of conviction). Ra Capital sale coverage

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).